|
| General Information |
| Business: |
We are a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics. As a class, biologics, which include mAbs and fusion proteins, have transformed human medicine in recent decades and represent some of the top-selling therapies on the market today. Our proprietary PETization platform is an algorithmic approach that enables us to rapidly create mAbs that are designed to be recognized as “self” or “native” by an animal’s immune system, a property we refer to as “100% species-specificity.” PETization is also designed to build upon the safety and efficacy data from clinically-tested human therapies to create new therapies for companion animals, thereby reducing clinical risk and development cost. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
21 |
Founded: |
2010 |
|
| Contact Information |
| Address: |
NIBRT, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -8.0 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
NVET |
| Shares (millions): |
4.0 |
| Price Range: |
$10.00 - $10.00 |
| Est.$ Volume |
$ 40.0 mil |
| Manager / Joint Managers |
BofA Merrill Lynch/ Cowen and Company |
| Co Managers |
Piper Jaffray/ JMP Securities |
| Expected to Trade |
2/5/2015 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
